News

Newsletter

Newsletter 2014.07 – ANVISA publishes resolutions on new procedures relative to marketing authorization in Brazil: RDC #58 and #60/2014

The main law regulating the health system in Brazil – Law #6,360 dated 1976 – establishes that each and every drug available in the pharmaceutical market must be approved by the Ministry of Health. Since the creation of the Brazilian FDA (called ANVISA), this autonomous autarchy subordinated to the Ministry of Health is in charge of issuing marketing authorization for drugs for human use and of establishing specific resolutions in order to regulate each of the existing categories of medicaments, such as the new drugs, generics, similars, biologicals.

According to ANVISA’s requirements, the documentation submitted by the manufacturers of both generic and similar drugs, upon applying for marketing approval, is significantly simplified compared to the reference product (the so-called “abridged process”), as only pharmaceutical equivalence and relative bioavailability/ bioequivalence assays are required to obtain approval for products pertaining to these categories.

It should be noted that, since the publication of Resolutions RDC #133 (new applications for marketing approval) and RDC #134 (similars, already approved), both dated May 29, 2003, ANVISA has begun to require proof of therapeutic equivalence also for similar drugs; therefore, it is estimated that all manufacturers of these products will have complied with such requirement by the end of 2014.

Accordingly, studies of pharmaceutical equivalence and bioavailability/bioequivalence became necessary in order to obtain marketing authorization for both generic and similar drugs, although the latter were not then yet considered to be interchangeable with the reference product.

Back

Last related news

April 28, 2022

Have you heard about the Web 3.0?

Web 3.0 is the new global trend that will impact modern society and the way people relate to the internet. It refers Have you heard about the Web 3.0?

Ler notícia

March 28, 2022

Brazilian PTOs publishes a technical note providing guidance on the patentability of elite events

On March 17, 2022, the BPTO released the INPI/CPAPD technical note No. 01/2022, which provides guidance on the patentability of inventions involving Brazilian PTOs publishes a technical note providing guidance on the patentability of elite events

Ler notícia

February 11, 2022

Data Protection becomes a fundamental right in Brazil

Yesterday (Feb. 10, 2022), the Brazilian Senate approved the Constitutional Amendment no. 115/2022, originated in the Proposal for Constitutional Amendment no. 17/2019, Data Protection becomes a fundamental right in Brazil

Ler notícia